All In Biotech

Investigational drug · Phase 3

Remimazolam Tosilate

Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Sedation in the ICU, Operative Sedation of Pediatric, Operative Sedation of Adolescent Patients.

Phase 3

Last checked: Nov 20, 2026Latest source record: Jun 4, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 3

Industry-sponsored trials

Phase 2 and 3 trials

2

0 still active

All registered trials

28

Any phase or sponsor naming "Remimazolam Tosilate"

First trial start

2023

Jun 27, 2023

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "Remimazolam Tosilate", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Sedation in the ICU
  • Operative Sedation of Pediatric
  • Operative Sedation of Adolescent Patients

Approved drugs for the same conditions: Pain and anesthesia

Largest trials

Live from ClinicalTrials.gov: studies naming "Remimazolam Tosilate" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 59 on PubMed

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.